Session Details

Hot Line: Late-Breaking Clinical Trials 1
27 Aug 11:00 - 12:35 Miscellaneous Hot Line Barcelona - Main Auditorium
Chairpersons: Jeroen BAX (Leiden, Netherlands), Barbara CASADEI (Oxford, United Kingdom)

Abstract Access slides, videos, reports online via ESC Congress 365 Other resources

Presentations list

Time
 
FP Nr
 
Title
 
Speakers
 
Related documents
11:001145Routine versus aggressive upstream rhythm control for prevention of early atrial fibrillation in heart failure, the RACE 3 studyIsabelle C VAN GELDER (Groningen, Netherlands)
11:101146Discussant review: Routine versus aggressive upstream rhythm control for prevention of early atrial fibrillation in heart failure, the RACE 3 study. Josep BRUGADA TERRADELLAS (Barcelona, Spain)
11:151147Panel discussion. 
11:181148Catheter ablation versus standard conventional treatment in patients with left ventricular dysfunction and atrial fibrillation: the CASTLE-AF trialNassir MARROUCHE (Salt Lake City, United States of America)
11:281149Discussant review: Catheter ablation versus standard conventional treatment in patients with left ventricular dysfunction and atrial fibrillation: the CASTLE-AF trialCarina BLOMSTROM-LUNDQVIST (Uppsala, Sweden)
11:331150Panel discussion. 
11:361154Cardiovascular OutcoMes for People using Anticoagulation StrategieS (COMPASS) trial: Primary Results John William EIKELBOOM (Hamilton, Canada)
11:461155Discussant review: Cardiovascular OutcoMes for People using Anticoagulation StrategieS (COMPASS) trial: Primary ResultsEugene BRAUNWALD (Boston, United States of America)
11:511156Panel discussion. 
11:541157COMPASS PAD- Cardiovascular OutcoMes for People using Anticoagulation StrategieS trial: Results in Patients with Peripheral Artery Disease.Sonia ANAND (Hamilton, Canada)
12:041158Discussant review: Cardiovascular OutcoMes for People using Anticoagulation StrategieS (COMPASS) trial: Results in Patients with Coronary Artery Disease and in patients with Peripheral Artery Disease.Lars WALLENTIN (Uppsala, Sweden)
12:091153Panel discussion. 
12:121151CANTOS - The Canakinumab Anti-Inflammatory Thrombosis Outcomes Study Paul M RIDKER (Boston, United States of America)
12:271152Discussant review: CANTOS - The Canakinumab Anti-Inflammatory Thrombosis Outcomes Study Malte KELM (Duesseldorf, Germany)
12:321159Panel discussion.